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Abstract
Background: Because of the late clinical presentation of biliary tract cancer (BTC), only 10% of patients are eligible
for curative surgery. Even among those patients who have undergone curative surgery, most patients develop
recurrent cancer. This study is to determine the clinical role of
18F-FDG PET/CT during post-operative surveillance of
suspected recurrent BTC based on symptoms, laboratory findings and contrast-enhanced CT (ceCT) findings.
Methods: We consecutively enrolled 50 patients with BTC who underwent curative surgery. An
18F-FDG PET/CT
was obtained for assessment of recurrence based on clinical suspicion during post-operative surveillance. The final
confirmation of recurrence was determined pathologically or clinically. When a pathologic confirmation was
impossible or inconclusive, a clinical confirmation was used by radiologic correlation with subsequent follow-up
ceCT at a minimum of 3-month intervals. Diagnostic efficacy was evaluated by comparing the results of ceCT and
18F-FDG PET/CT with the final diagnosis.
Results: Among the 50 patients, 34(68%) were confirmed to have a recurrence. PET/CT showed higher sensitivity
(88% vs. 76%, p = 0.16) and accuracy (82% vs. 66%, p = 0.11) for recurrence compared to ceCT, even though the
difference was not significant. The positive (86% vs. 74%, p = 0.72) and negative predictive values for recurrence (73%
vs. 47%, p = 0.55) were not significantly different between PET/CT and ceCT. However, an additional PET/CT on ceCT
significantly improved the sensitivity than did a ceCT alone (94% [32/34] for PET/CT on ceCT vs. 76% [26/34] for ceCT
alone, p = 0.03) without increasing the specificity, positive predictive value, and negative predictive value.
Conclusions:
18F-FDG PET/CT alone is not more sensitive or specific than ceCT in the detection of recurrent BTC
after curative surgery. These results do not reach statistical significance, probably due to the low number of
patients. However, an additional
18F-FDG PET/CT on ceCT significantly improves the sensitivity of detecting
recurrences.
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Background
Biliary tract cancers (BTCs) are rare, highly lethal carci-
nomas that develop from the epithelium of the gallblad-
der and bile duct. Because of the late clinical
presentation of BTCs, only 10% of patients are eligible
for curative surgery [1,2]. Even among those patients
who have undergone curative surgery, a majority of the
patients develop recurrent cancer, supporting the notor-
iously poor prognosis of BTCs. Nevertheless, the prompt
diagnosis of recurrent BTC could allow for prompt
treatment and reduce the number of unnecessary inter-
ventions [2]. Therefore, the surveillance of BTC recur-
rence is important.
According to the practice guidelines for detecting BTC
recurrences, a physical examination with routine labora-
tory tests, every 3-4 months for the first 3 years after
surgery and then every 6 months until the 5th post-
operative year, is recommended [3]. Additionally,
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mended that surveillance includes radiologic evaluation
with an abdominal CT scan every 6 months for 2-3
years [3,4]. The role of tumor marker (CA19-9) as sur-
veillance is not clear, but constantly rising levels often
p r e c e d er a d i o l o g i ce v i d e n c eo fr e c u r r e n c eb yan u m b e r
of months [3].
During surveillance, the definitive diagnosis of suspi-
cious lesions on contrast-enhanced CT (ceCT) scans as
recurrent cancer can only be made by pathologic confir-
mation. However, a valid biopsy is not always possible
as the lesion of interest is often small in size and located
deep adjacent to large vessels or vital structures. There
are also cases in which no definite recurrent lesions are
detected on ceCT following measurement of elevated
tumor markers, such as CA19-9 or CEA, with or with-
out suspicious symptoms. In these cases, recurrence sta-
tus must only be determined clinically by considering
the clinical context, including symptoms, laboratory
findings, and CT findings.
Recently,
18F-fluorodeoxyglucose positron emission
tomography integrated with computed tomography
(
18F-FDG PET/CT) has been introduced and consid-
ered to be a valuable imaging tool by combining ana-
tomic and metabolic imaging information in cancer
[5]. In particular, the usefulness of
18F-FDG PET/CT
is reported in several studies for staging of breast,
colorectal, lung, and head and neck cancers, cholan-
giocarcinomas, lymphomas, and for detecting recur-
rences of breast, colorectal, lung and cervical cancers
[6-12]. However, a study concerning the role of
18F-
FDG PET/CT during surveillance of BTCs is scarce
[ 1 3 ] .T h e r e f o r e ,w ec o n d u c t e dt h i ss t u d yt oe v a l u a t e
and compare the diagnostic validity of ceCT and
18F-
FDG PET/CT in the assessment of BTC recurrence
after curative surgery. In addition, we searched for
correlation between maximal standardized uptake
value (SUVmax)i n
18F-FDG PET/CT and tumor
markers.
Methods
Patients
Between October 2003 and June 2008 we consecutively
enrolled 50 patients with BTCs who underwent curative
resection at Seoul National University Hospital and
obtained a
18F-FDG PET/CT for assessment of recur-
rence due based on clinical suspicion. All data were col-
lected and analyzed retrospectively.
Patients were classified as clinically suspicious for
recurrent BTC and underwent
18F-FDG PET/CT scans
when there is at least one of the following criteria: 1)
suspicious CT findings, 2) elevated tumor markers, such
as CA19-9 or CEA, 3) abnormal liver function tests,
and/or 4) suspicious clinical symptoms.
Contrast enhanced CT
All CT images were obtained using a multidetector-row
computed tomography (MDCT) scanner (Mx 8000, Phi-
lips Healthcare; or LightSpeed Ultra, GE Healthcare;
Sensation 16, Simens Healthcare). Each patient received
90 mL of nonionic contrast material that was adminis-
tered at a rate of 3.0-4.0 mL/s using a mechanical injec-
tor. For the MDCT examinations, 3- to 5-mm slice
thickness, and 3- to 5-mm reconstruction interval were
used. CT images were obtained during the arterial and
portal venous phases.
18F-FDG PET/CT
All scans were performed with one of two PET/CT sys-
tems (Philips Gemini Dual; Best, The Netherlands [from
October 2003 to the end of the study] or SIMENS Bio-
graph TruePoint; Germany [from November 2007 to the
end of the study]). After fasting for 8 hours, 5.18 MBq/
kg (0.14 mCi/kg) of FDG was injected. Then, all of the
subjects rested quietly for 1 hour. A whole-body
18F-
FDG PET scan was performed from the skull base to
the mid-thigh. The CT scan without contrast was per-
formed immediately prior to the PET scan with a multi-
detector 2-slice spiral CT scanner. For the whole-body
emission scan, 9-bed positions were examined at 3 min
per step. CT and PET images were reconstructed onto a
512 × 512 matrix and a 128 × 128 matrix, respectively,
and integrated after attenuation correction.
Data analysis and statistical methods
Two other board-certified radiologists, who were
blinded to the diagnosis, independently interpreted
ceCT images for the recurrence. All lesions on the ceCT
were interpreted as recurrent, equivocal, or benign. The
appearance of new malignant lesions in locoregional
area or distant site denotes disease recurrence. For the
confirmation of recurrence by ceCT, the RECIST cri-
teria were used [14]. When a postoperative image find-
ing was uneventful: no locoregional recurrence and no
distant metastasis, we can define a benign finding. If we
cannot differentiate recurrence from benign, the lesion
of interest is an equivocal finding. On statistical analysis,
equivocal lesions were regarded as benign. Abnormal
18F-FDG PET/CT lesions were assessed as benign or
malignant with respect to their location, patterns of
uptake, and SUVmax. Recurrence in the liver remnant or
operative site was categorized as locoregional recur-
rence. In addition, recurrences in other areas were cate-
gorized as metastases.
When evaluating findings of
18F-FDG PET/CT on
ceCT as recurrences, at least one image finding of
recurrence was necessary. However, benign findings on
both
18F-FDG PET/CT and ceCT were necessary to
interpret the lesions of interest as benign.
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18F-FDG PET/CT was considered the standard of refer-
ence. When a pathologic confirmation was possible, it
was considered the standard of reference. However,
when pathologic confirmation was impossible or incon-
clusive, we resorted to a clinical confirmation via radi-
ologic correlation with subsequent ceCT with a
minimum 3-month follow-up. Thus, no significant inter-
val change for at least 3-months of follow-up by ceCT
was required to confirm the lesion of interest as clini-
cally benign. If there is a significant increase in size of
lesion of interest, we can confirm the lesion is
malignant.
The diagnostic validity of ceCT,
18F-FDG PET/CT,
and the combination was evaluated by comparison with
the standard of reference. Overall and site-specific sensi-
tivity, specificity, positive predictive value, and negative
predictive value were calculated. McNemar’st e s ta n d
Fisher’s exact test were used to evaluate the efficacy of
ceCT,
18F-FDG PET/CT, and the combination. Receiver
operating characteristics (ROC) analysis was performed
for the detection of recurrent lesions of ceCT and
18F-
FDG PET/CT. All p values were two-sided in tests and
p values less than or equal to 0.05 were considered to
be statistically significant. All analyses were performed
using Stata 9.0 software (Stata Corp, College Station,
TX, USA).
Ethics
The study protocol was reviewed and approved by the
Institutional Review Board of Seoul National University
Hospital (IRB No: 1001-001-304). All studies were car-
ried out according to the Declaration of Helsinki guide-
lines for biomedical research.
Results
Patients
Fifty patients were enrolled. The patient characteris-
tics are shown in Table 1. Males comprised 74% of
the study patients (n = 37). The locations of tumors
were as follows: intrahepatic, 24%; common bile duct,
40%; ampullar of Vater, 28% and gallbladder, 8%.
According to the initial pathologic staging, 36% of the
patients were node-positive (≥ stage IIB in AJCC 6
th
classification) [15]. The 15 of 22 patients of observa-
tion group (68.2%) were recurred. Interestingly, 19 of
28 patients of adjuvant treatment group (67.9%) were
recurred.
Median time interval between ceCT and
18F-FDG
PET/CT was 17 days (range 1-70) and 17 patients had
the longer interval than 3 weeks. In all 50 patients, med-
ian overall survival was 52.5 months (95% CI: 41.1, -).
The median follow-up time was 49.1 months (range 5.1-
86, standard error 11.5).
Before
18F-FDG PET/CT was undertaken, there had
been suspicious CT lesions for recurrence in 30 patients.
Among 17 patients, there was at least 1 other suspicious
finding (elevated tumor marker, symptoms, and abnor-
mal liver function) in addition to suspicious CT findings
(Table 2).
Detection of Recurrence by
18F-FDG PET/CT and ceCT
The median interval between ceCT and
18F-FDG PET/
CT was 17 days (range, 1-70 days). The recurrence status
was determined in 6 patients based on pathologic assess-
ment and in 44 patients based on clinical findings.
Among the 50 patients, 34 had confirmed recurrences.
Only 6 patients were eligible for pathologic confirmation
(5 by biopsy, 1 by surgery): 4 lesions were recurred malig-
nancies and 1 lesion was benign. However, a biopsy of
the other 1 lesion was inconclusive because of limited
Table 1 Clinicopathologic Characteristics of Patients
Characteristics No. of
patients
(N = 50)
Age Mean (range) 60 years
(33-77)
Gender Male: Female 37 (74%):
13 (26%)
Tumor type Intrahepatic
cholangiocarcinoma
12 (24%)
CBD cancer 20 (40%)
Ampulla of Vater
cancer
14 (28%)
Gallbladder cancer 4 (8%)
Pathologic stage
Intrahepatic I 9 (18%)
IIIC 3 (6%)
Extrahepatic IA 3 (6%)
IB 10 (20%)
IIA 10 (20%)
IIB 14 (28%)
III 1 (2%)
Tumor differentiation Well differentiated 8 (16%)
Moderate
differentiated
34 (68%)
Poorly
differentiated
4 (8%)
Not classified 4 (8%)
Post-operative treatment Observation 22 (44%)
Adjuvant
chemotherapy
3 (6%)
Adjuvant
chemoradiation
25 (50%)
Interval between post-operative
treatment and suspicion of
recurrence
Median (range) 10.7
months
(0.5-97.3)
Interval between ceCT and PET/CT Median (range) 17 days
(1-70)
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included), 16 were recurrent near the locoregional area
and 16 were recurrent in the lymph nodes (Table 3).
Overall and site-specific sensitivity, specificity, positive
predictive value, and negative predictive value according
to each image modality are presented in Tables 4 and 5.
PET/CT showed higher sensitivity and accuracy com-
pared to ceCT, but the results did not reach statistical
significance. While an additional PET/CT on ceCT sig-
nificantly improved the overall sensitivity (p = 0.03), the
overall diagnostic efficacy between ceCT alone and
PET/CT alone, or ceCT alone and PET/CT on ceCT,
was not significantly different. The lower specificity in
combination of ceCT and PET/CT than ceCT or PET/
CT alone can be explained that benign findings from
b o t hc e C Ta n dP E T / C Tw e r en e c e s s a r yt oi n t e r p r e tt h e
lesions of interest as benign: among 7 patients identified
as benign in ceCT and 11 patients identified as benign
in PET/CT, only 6 patients with benign findings from
both ceCT and PET/CT (Table 4). In addition, the site-
specific diagnostic efficacy did not show any significant
difference between each diagnostic modality (Table 5).
The ROC analysis indicated that a PET/CT had the
higher overall accuracy for the detection of recurrence
than ceCT (AUC 0.788 in PET/CT vs.A U C0 . 6 0 3i n
ceCT; Figure 1).
Tumor marker and
18F-FDG uptake
When there was an indication for
18F-FDG PET/CT, 14
patients had elevated CA19-9 levels compared to post-
operative levels (Table 2). Among 14 patients, 11 were
confirmed to have recurrences. Although the CA19-9
level was elevated, the difference in mean SUVmax in the
lesion of interest was not statistically significant (p =
0.42).
The mean SUVmax of recurrent sites was 4.30 (95% CI,
3.04-5.36), which was higher than 2.52 (95%CI, 1.45-
3.58) of the non-recurrent sites and of borderline signifi-
cance (p = 0.06). However, the mean SUVmax by each
recurrent site was similar (4.53 in locoregional areas, 4.4
in lymph node areas). Among 34 patients with recurrent
disease, we calculated the median value of SUVmax
(3.35) and compared overall survival between patients
with SUVmax of 3.35 or less and greater than 3.35. How-
ever, the survival probability for patients with SUVmax of
3.35 or less was not significantly higher than patients
with SUVmax greater than 3.35 (p = 0.40).
Clinical decisions based on imaging findings
Figure 2 presents a flow diagram showing the identifica-
tion of recurrences based on imaging findings. Of the 50
study patients, 36 lesions had concordant results
between ceCT and
18F-FDG PET/CT (total agreement,
72%; kappa statistics = 0.33). For 14 lesions with discor-
dant results,
18F-FDG PET/CT was 79% identical to the
final recurrence status (11 of 14). In contrast, ceCT was
21% identical to the final recurrence status (3 of 14).
Discussion
The objective of the current study was to determine the
clinical role of
18F-FDG PET/CT in the assessment of
BTC recurrences when clinicians suspected recurrence
during surveillance based on symptoms, laboratory find-
ings (including tumor markers), and CT findings. Our
data suggest that
18F-FDG PET/CT alone is not more
sensitive or specific than ceCT in the detection of recur-
rent BTCs. However, these results do not reach statisti-
cal significance, probably due to the low number of
patients. On the other hand, an additional
18F-FDG
PET/CT on ceCT significantly improves the sensitivity
in detecting recurrences.
Previous studies have evaluated the utility of
18F-FDG
PET or PET/CT in BTCs [11,13,16-18]. The study by
Kim et al enrolled 123 patients with suspected and
potentially operable cholangiocarcinomas, and demon-
strated that PET/CT showed no advantage over ceCT in
Table 2 Clinical Suspicion before
18F-FDG PET/CT
Suspicious
CT
findings
Elevated
tumor
markers
Concerning
clinical
symptoms*
Abnormal
liver function
tests†
No. of
patients
(N = 50)
+ - - - 30 (60%)
++ - - 10 (20%)
+ - + - 3 (6%)
+ -- + 3 (6%)
++ + + 1 (2%)
- + - - 2 (4%)
- ++ - 1 (2%)
* Significant abdominal pain
† Reflecting cholestasis
Table 3 Detection of recurrence
No. of
patients
(N = 50)
Recurrence Yes 34 (68%)
No 16 (32%)
Pathologic confirmation 6 (12%)
Clinical confirmation 44 (88%)
No. of lesions
(n = 39)
Recurrence site
(multiple counted)
Locoregional recurrence (Liver
or anastomosis site)
16 (41%)
Distant metastasis 23 (60%)
Lymph node 16 (42%)
Peritoneum 3 (8%)
Other (Lung, bone) 4 (10%)
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in the diagnosis of regional lymph node and distant
metastases [11]. Petrowsky et al reported that PET/CT
and ceCT provided comparable accuracy for primary
cholangiocarcinoma, but PET/CT was particularly valu-
able in detecting unsuspected distant metastases which
were not diagnosed by standard imaging in the staging
of patients with gallbladder cancer and cholangiocarci-
nomas (12/12 in PET/CT vs. 3/12 in ceCT; p < 0.001)
[17]. In these studies,
18F-FDG PET or PET/CT did not
have a statistically significant advantage over ceCT in
the diagnosis of primary tumors, but was valuable in
identifying occult distant metastases which were not
detected by conventional imaging. Only Corvera et al
identified the role of
18F-FDG PET in detecting disease
recurrences after resection in their analysis and reported
that
18F-FDG PET was helpful to clarify recurrences
with 76% of sensitivity [16]. Thus,
18F-FDG PET was
merely confirmatory because recurrences were also
identified on conventional imaging.
Unlike the aforementioned studies, the current analy-
sis documented the complementary role of
18F-FDG
PET/CT under a frequently encountered situation in the
clinic in which clinicians suspected a recurrence. Of 50
patients, 36 had concordant results between ceCT and
subsequent
18F-FDG PET/CT, and
18F-FDG PET/CT
was 83% (30/36) consistent with the final recurrence sta-
tus (Figure 2). Moreover, an additional PET/CT
correctly identified six false-negative cases as recur-
rences which were interpreted as benign or equivocal by
ceCT. This resulted in a significant increase in sensitiv-
ity (88% vs.9 4 % ,p = 0.03) and suggested a complemen-
tary role of
18F-FDG PET/CT beyond ceCT when
clinicians suspected a recurrence.
Of these six false-negative cases by ceCT, three were first
interpreted as post-operative inflammatory changes. For
the other three cases, lymph node metastasis was not con-
fidently interpreted as a recurrence due to the insignificant
size. However, the
18F-FDG PET/CT was interpreted as a
recurrence in these lesions based on the high
18F-FDG
uptake. From this information, five patients could receive
palliative chemotherapy, whereas the other patient could
not receive chemotherapy because of poor performance
status. Moreover, an additional PET/CT showed no
18F-
FDG uptake in five false-positive cases by ceCT, which
provided decisive information to the clinicians. Among 14
patients with discordant results, 11 patients (11/14, 79%)
was treated regarding to the results of PET/CT. In this
context, when ceCT is inconclusive for identifying post-
operative changes and the lymph nodes are of borderline
size, a discernible role for
18F-FDG PET/CT is feasible.
This complementary role of
18F-FDG PET/CT during
surveillance has been assessed in other cancers. Specifi-
cally, Radan et al described patients with breast cancer
and rising tumor markers in which
18F-FDG PET/CT
was superior to CT for diagnosis of tumor recurrence,
Table 4 Diagnosis of tumor recurrence by ceCT and
18F-FDG PET/CT
ceCT PET/CT Combination of ceCT and PET/CT p-value
ceCT vs PET/CT ceCT vs Combination
Sensitivity* 26/34 (76%) 30/34 (88%) 32/34 (94%) 0.16 0.03
Specificity* 7/16 (44%) 11/16 (69%) 6/16 (38%) 0.10 1.00
PPV 26/35 (74%) 30/35 (86%) 32/42 (76%) 0.72 1.00
NPV 7/15 (47%) 11/15 (73%) 6/8 (75%) 0.55 1.00
Accuracy 33/50 (66%) 41/50 (82%) 38/50 (76%) 0.11 0.38
*p-value was calculated by McNemar’s test
PPV = positive predictive value; NPV = negative predictive value
Table 5 Site-specific efficacy of ceCT and
18F-FDG PET/CT
Site ceCT PET/CT Combination of ceCT and PET/CT p-value
ceCT vs PET/CT ceCT vs Combination
Sensitivity* 88% (14/16) 88% (14/16) 100% (16/16) 0.10 0.5
Locoregional area (n = 16) Specificity* 86% (37/43) 93% (40/43) 84% (36/43) 0.38 1.0
PPV 70% (14/20) 82% (14/17) 70% (16/23) 0.46 1.0
NPV 95% (37/39) 93% (40/42) 100% (36/36) 1.0 0.49
Sensitivity* 63% (10/16) 94% (15/16) 94% (15/16) 0.08 0.08
Lymph node (n = 16) Specificity* 93% (40/43) 95% (41/43) 91% (39/43) 0.91 0.74
PPV 77% (10/13) 88% (15/17) 79% (15/19) 0.63 0.61
NPV 87% (40/46) 98% (41/43) 98% (39/40) 0.11 0.12
* p-value was calculated by McNemar’s test
PPV = positive predictive value; NPV = negative predictive value
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ment of 51% of the patients [19]. In addition, Guo et al
evaluated the role of
18F-FDG PET/CT in patients with
possibly recurrent esophageal squamous cell carcinoma
who underwent definitive treatment and displayed a
remarkable sensitivity and a high specificity and accu-
racy at regional and distant sites for recurrent esopha-
geal squamous cell carcinoma [20].
Furukama et al. evaluated the prognostic significance of
FDG uptake on PET in patients with biliary tract cancer
and demonstrated the SUVmax of 6.3 to be the optimal
cutoff point for survival [21]. In addition, their data
showed that the SUVmax was one of the significant prog-
nostic factors for overall survival in univariate analysis.
However, our data did not show that the SUVmax was the
significant prognostic factor for overall survival, probably
due to the low number of patients and selection bias.
Our study had limitations other than retrospective
design. First of all, the majority of recurrent cases were
confirmed clinically. Our standard for non-recurrence
required no significant changes in the lesion for a mini-
mum of 3 months; however, such a criterion has not
been validated and may be insufficient for confirmation.
Second, the validity of
18F-FDG PET/CT may have been
overestimated because the nuclear medicine physicians
were aware of the findings of the corresponding ceCT.
Lastly, the longer time interval between ceCT and PET/
CT and the different characteristics of 3 CT scanners
between the period of 2003 to 2008 might influence the
results. Nevertheless, our study has significance in
demonstrating the complementary role of
18F-FDG
PET/CT in a commonly encountered clinical situation
in which clinicians suspect BTC recurrence by elusive
clinical manifestations with equivocal or inconclusive
conventional imaging. Additionally, as the most modern
PET/CT scanners allow for fully diagnostic ceCT scans,
contrast enhanced diagnostic PET/CT could be
Figure 1 Receiver Operating Characteristic Curve of ceCT and
PET/CT for Detection of Recurrence.
Figure 2 Flow Diagram Showing Identification of Recurrence based on Imaging Finding.
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of suspected recurrence.
Conclusions
We demonstrated that
18F-FDG PET/CT significantly
improved the overall sensitivity of detecting BTC recur-
rences when ceCT was inconclusive and did not corre-
spond to the clinical presentation. And
18F-FDG PET/CT
was as sensitive and specific as ceCT in the detection of
recurrent BTCs. Therefore, if both image modalities are
discordant,
18F-FDG PET/CT is worthy of being weighted.
Further prospective studies are necessary to establish the
role of
18F-FDG PET/CT during surveillance.
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